Market News Latest

The market size of Functional Dyspepsia is anticipated to increase during the study period (2018-30) in the 7MM

 Breaking News
  • No posts were found

The market size of Functional Dyspepsia is anticipated to increase during the study period (2018-30) in the 7MM

July 30
16:12 2021
The market size of Functional Dyspepsia is anticipated to increase during the study period (2018-30) in the 7MM

Functional Dyspepsia Market
The launch of therapies such as Naronapride (ATI-7505), RQ-00000010 (5-HT4 partial agonist), ISOT-101, and others are anticipated to provide a major push to the growth of the Functional Dyspepsia market size in the forecast period 2021-30 in the 7MM.

DelveInsight’s Functional Dyspepsia market report provides a comprehensive understanding of the Functional Dyspepsia, historical and projected epidemiology, and Functional Dyspepsia market trends in the 7MM (the United States, the EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan). The report also discusses current Functional Dyspepsia treatment practices/algorithms, Functional Dyspepsia market drivers, Functional Dyspepsia market barriers, and unmet medical needs.

Some of the Important Findings from the Functional Dyspepsia Market Report

  • According to Madisch et al. (2018), Functional Dyspepsia is one of the most frequent functional disorders, with a prevalence of 10–20%. 

  • According to Longstreth et al. (2019), roughly 25% of dyspepsia patients have an underlying organic cause, while nearly 75% have Functional Dyspepsia with no underlying cause on diagnostic examination.

  • Key players, such as Zeria Pharmaceutical, RaQualia Pharma, ISOThrive, Jiangxi Qingfeng Pharmaceutical, Renexxion, Sinovant Sciences, and others are involved in developing a treatment for Functional Dyspepsia. 

  • Naronapride (ATI-7505), a Renexxion product, has completed many Phase II clinical trials for the treatment of Functional Dyspepsia, gastrointestinal diseases such as CIC, and GERD. It comes in the form of an oral tablet. Sinovant Sciences and Renexxion announced a collaboration in July 2018 to pursue the development of Naronapride in Greater China.

  • RaQualia Pharma has completed the Phase I clinical trial of RQ-00000010 (5-HT4 partial agonist) in the United Kingdom for Gastroparesis, Functional Dyspepsia, and Chronic Constipation.

  • ISOThrive’s ISOT-101 is a patented product. It is intended to change the normal localized microbiome at the Lower Esophageal Sphincter (LES) from an unusual gram-negative predominant state to a normal predominantly gram-positive healthy state, thereby stopping acid reflux at its source.

Request for sample for better understanding about the functional dyspepsia @ Functional Dyspepsia Treatment Guidelines

The Functional Dyspepsia market report also includes current treatment practices, emerging drugs, individual Functional Dyspepsia therapy market share, and current and forecasted Functional Dyspepsia market Size from 2018 to 2030, segmented by seven major markets. 

Functional Dyspepsia: Overview

Functional Dyspepsia refers to indigestion symptoms that reoccur but have no obvious cause. Functional Dyspepsia is also known as non-ulcer stomach pain or dyspepsia. Although signs and symptoms are mostly intermittent, Functional Dyspepsia is common and can last for a long time. These symptoms and signs are similar to those of an ulcer, such as pain or discomfort in your upper abdomen, which is frequently accompanied by bloating, belching, and nausea.

Functional Dyspepsia Epidemiology Segmentation

The Functional Dyspepsia report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:

  • Functional Dyspepsia Total Prevalent Cases

  • Functional Dyspepsia Gender-Specific Cases

  • Total Prevalent Cases of Subgroups of Functional Dyspepsia 

  • Functional Dyspepsia Treatable Prevalent Cases

Functional Dyspepsia Treatment Landscape 

The major options for Functional Dyspepsia treatment include:

  • Helicobacter pylori eradication

  • Prokinetic agents 

  • Antidepressant therapy

  • Conventional medical therapies

Functional Dyspepsia Market

The launch of therapies such as Naronapride (ATI-7505), RQ-00000010 (5-HT4 partial agonist), ISOT-101, and others by key pharmaceutical companies such as Zeria Pharmaceutical, RaQualia Pharma, ISOThrive, and several others is anticipated to provide a major push to the growth of the Functional Dyspepsia market size in the forecast period 2021-30 in the 7MM. 

Reach out for more insights on market @ Functional Dyspepsia Market Size

Functional Dyspepsia Pipeline Therapies and Key Companies 

  • ISOT-101: ISOThrive 

  • Naronapride: Renexxion

  • RQ-00000010: RaQualia Pharma

  • Aolanti Weipang Tablets: Jiangxi Qingfeng Pharmaceutical

Table of Contents 

1.

Report Introduction

2.

Executive Summary of Functional Dyspepsia

3.

SWOT Analysis of Functional Dyspepsia 

4.

Functional Dyspepsia: Patient Share (%) Overview at a Glance

5.

Functional Dyspepsia: Market Overview (%) at a Glance

6.

Functional Dyspepsia Disease Background and Overview 

7.

Functional Dyspepsia Epidemiology and Patient Population

8.

Country-Specific Patient Population of Functional Dyspepsia

9.

Functional Dyspepsia Current Treatment and Medical Practices

10.

Functional Dyspepsia Patient Journey

11.

Functional Dyspepsia Unmet Needs

12.

Functional Dyspepsia Key Endpoint of Clinical Trials

13.

Functional Dyspepsia Marketed Products

14.

Functional Dyspepsia Emerging Therapies

15.

Conjoint Analysis of Functional Dyspepsia Therapies

16.

Functional Dyspepsia: Market Size of 7MM

17.

Functional Dyspepsia Country-Wise Market Analysis (2018–2030)

18.

Market Access and Reimbursement of Functional Dyspepsia

19.

Functional Dyspepsia Market drivers

20.

Functional Dyspepsia Market barriers

21.

Appendix

22.

DelveInsight Capabilities

23.

Disclaimer

24.

About DelveInsight

For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare, and Biotech Blog Posts

Related Reports

Diabetic Foot Ulcer Market

Get comprehensive historical and forecast analysis of Diabetic Foot Ulcer Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Amniox, TissueTech, Helixmith, Aurealis Therapeutics, Microbion Corporation, Mallinckrodt, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/